MedTrace Logo

Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)

NCT04087746 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2019-09-12

No results posted yet for this study

Summary

Diabetic macular edema (DME) is a sign of diabetic retinopathy that affects central vision. It is also a leading cause of visual decline in younger patients, especially in developing countries like our Arab community. Intra-vitrreal injection of anti-vascular endothelial growth factor (AVEGF) in management of DME had significant improvement in the final logMAR Un-corrected Distant Visual Acuity ( UCDVA) and logMAR Best Corrected Distant Visual Acuity (BCDVA), as well as reduction in the central retinal thickness from baseline measurement.

Conditions

Interventions

DRUG

Aflibercept

Intra-vitreal injection of AVEGF AFLIBERCEPT in group I

DRUG

Ranibizumab

Intra-vitreal injection of AVEGF Ranibizumab in group 2

Sponsors & Collaborators

  • Minia University

    lead OTHER

Principal Investigators

  • Shaaban AM Elwan, MD · Minia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-01-31
Completion
2019-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04087746 on ClinicalTrials.gov